Peter Noertersheuser

793 total citations
22 papers, 626 citations indexed

About

Peter Noertersheuser is a scholar working on Rheumatology, Obstetrics and Gynecology and Reproductive Medicine. According to data from OpenAlex, Peter Noertersheuser has authored 22 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 6 papers in Obstetrics and Gynecology and 6 papers in Reproductive Medicine. Recurrent topics in Peter Noertersheuser's work include Endometriosis Research and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Uterine Myomas and Treatments (5 papers). Peter Noertersheuser is often cited by papers focused on Endometriosis Research and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Uterine Myomas and Treatments (5 papers). Peter Noertersheuser collaborates with scholars based in United States, Germany and Austria. Peter Noertersheuser's co-authors include Ahmed Nader, Nael M. Mostafa, Walid M. Awni, Michael H. Weisman, Harold E. Paulus, Edward Keystone, Larry W. Moreland, Michael E. Weinblatt, Daniel E. Furst and Steven Fischkoff and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Peter Noertersheuser

20 papers receiving 612 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Noertersheuser United States 10 181 165 141 118 106 22 626
Christophe Passot France 11 172 1.0× 84 0.5× 92 0.7× 54 0.5× 47 0.4× 28 514
Eva Pérez‐Pampín Spain 20 331 1.8× 665 4.0× 182 1.3× 173 1.5× 64 0.6× 62 1.1k
Nicole Straetmans Belgium 17 151 0.8× 35 0.2× 183 1.3× 272 2.3× 50 0.5× 44 1.1k
Claudia Baratè Italy 19 127 0.7× 207 1.3× 225 1.6× 513 4.3× 48 0.5× 56 1.0k
Patrizia Lista Italy 12 252 1.4× 27 0.2× 181 1.3× 325 2.8× 78 0.7× 34 735
Jingru Tian China 9 217 1.2× 249 1.5× 97 0.7× 33 0.3× 32 0.3× 23 610
J. Casper Germany 17 179 1.0× 45 0.3× 258 1.8× 395 3.3× 38 0.4× 41 970
Ch. Marth Austria 14 289 1.6× 17 0.1× 193 1.4× 277 2.3× 67 0.6× 50 811
Daniel Espinouse France 19 181 1.0× 35 0.2× 102 0.7× 410 3.5× 71 0.7× 43 1.3k
Lode Goethals Belgium 12 220 1.2× 44 0.3× 258 1.8× 12 0.1× 32 0.3× 31 688

Countries citing papers authored by Peter Noertersheuser

Since Specialization
Citations

This map shows the geographic impact of Peter Noertersheuser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Noertersheuser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Noertersheuser more than expected).

Fields of papers citing papers by Peter Noertersheuser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Noertersheuser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Noertersheuser. The network helps show where Peter Noertersheuser may publish in the future.

Co-authorship network of co-authors of Peter Noertersheuser

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Noertersheuser. A scholar is included among the top collaborators of Peter Noertersheuser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Noertersheuser. Peter Noertersheuser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Mohan, et al.. (2021). Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clinical Pharmacokinetics. 61(4). 577–587. 4 indexed citations
2.
Stodtmann, Sven, Ahmed Nader, Akshanth R. Polepally, et al.. (2021). Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis. Clinical and Translational Science. 14(4). 1611–1619. 3 indexed citations
3.
Gao, Wei, Nael M. Mostafa, Peter Noertersheuser, et al.. (2021). Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women. Clinical and Translational Science. 14(4). 1452–1463. 4 indexed citations
4.
Polepally, Akshanth R., et al.. (2020). Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model. CPT Pharmacometrics & Systems Pharmacology. 9(8). 466–475. 3 indexed citations
5.
Suleiman, Ahmed A., Ahmed Nader, Akshanth R. Polepally, et al.. (2020). Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain. CPT Pharmacometrics & Systems Pharmacology. 9(11). 639–648. 11 indexed citations
6.
7.
Shebley, Mohamad, Akshanth R. Polepally, Ahmed Nader, et al.. (2019). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical Pharmacokinetics. 59(3). 297–309. 45 indexed citations
8.
Nader, Ahmed, et al.. (2019). Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis. Clinical Pharmacology & Therapeutics. 107(4). 994–1003. 25 indexed citations
9.
Mohamed, Mohamed‐Eslam F., et al.. (2019). FRI0138 EXPOSURE-RESPONSE ANALYSES OF UPADACITINIB EFFICACY AND SAFETY IN RHEUMATOID ARTHRITIS – ANALYSES OF PHASE 2 AND 3 STUDIES. Annals of the Rheumatic Diseases. 78. 739–740. 2 indexed citations
10.
Nader, Ahmed, Akshanth R. Polepally, Mohan Liu, et al.. (2018). Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical Pharmacokinetics. 57(10). 1295–1306. 23 indexed citations
11.
Smolen, Josef S, Nael M. Mostafa, Xin Huang, et al.. (2018). THU0185 The value of adalimumab trough levels and clinical assessments in predicting clinical response in patients with established rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases. 77. 311–311. 2 indexed citations
12.
Nader, Ahmed, et al.. (2017). Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa. Clinical Pharmacokinetics. 56(9). 1091–1102. 33 indexed citations
13.
Mostafa, Nael M., Ahmed Nader, Peter Noertersheuser, Martin M. Okun, & Walid M. Awni. (2016). Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 31(3). 490–497. 39 indexed citations
14.
Yang, Jianning, Peter Noertersheuser, Sven Mensing, et al.. (2014). Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemotherapy and Pharmacology. 74(3). 593–602. 118 indexed citations
15.
Notario, Gerard, et al.. (2013). Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis. Pulmonary Pharmacology & Therapeutics. 26(6). 666–671. 29 indexed citations
16.
Noertersheuser, Peter, Shringi Sharma, Roopal Thakkar, et al.. (2013). Sa1209 Factors Affecting Adalimumab Pharmacokinetics in Adult Patients With Moderate to Severe CD. Gastroenterology. 144(5). S–230. 4 indexed citations
17.
Awni, Walid M., Sanjeev Sharma, Nael M. Mostafa, et al.. (2013). P412 Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis. Journal of Crohn s and Colitis. 7. S175–S175. 1 indexed citations
18.
Noertersheuser, Peter, Sherven Sharma, Roopal Thakkar, et al.. (2013). P493 Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD. Journal of Crohn s and Colitis. 7. S207–S207. 1 indexed citations
19.
Noertersheuser, Peter, Rajendra Pradhan, Cheri E. Klein, et al.. (2011). Exposure—Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis. The Journal of Clinical Pharmacology. 52(8). 1162–1173.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Passot Breakdown of academic impact, for papers by Eva Pérez‐Pampín Breakdown of academic impact, for papers by Nicole Straetmans Breakdown of academic impact, for papers by Claudia Baratè Breakdown of academic impact, for papers by Patrizia Lista Breakdown of academic impact, for papers by Jingru Tian Breakdown of academic impact, for papers by J. Casper Breakdown of academic impact, for papers by Ch. Marth Breakdown of academic impact, for papers by Daniel Espinouse Breakdown of academic impact, for papers by Lode Goethals
Rankless by CCL
2026